Third-Party Manufacturer’s 483 Draws 2<sup>nd</sup> CRL for AbbVie’s Parkinson’s Candidate
The FDA issued a complete response letter (CRL) for foscarbidopa/foslevodopa (ABBV-951) based on observations from an inspection at one of AbbVie’s third-party manufacturing facilities, the company announced yesterday.
Source: Drug Industry Daily